Lihui Xu , Tingting Feng , Keyan Fang

Traditional Chinese Medicine Research Center, Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 3   
Received: 17 Apr., 2024    Accepted: 20 May, 2024    Published: 01 Jun., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The rapid rise of mRNA vaccines during the COVID-19 pandemic has demonstrated exceptional efficacy and safety. However, comprehensive studies on their long-term safety and efficacy across different populations are still ongoing. This study evaluates the safety and efficacy of mRNA vaccines in disease prevention based on clinical trial data, providing a basis for public health policy-making, vaccine promotion, and future vaccine development. By comparing the performance of mRNA vaccines with traditional vaccines, the study reveals their characteristics in terms of protective efficacy, adverse reactions, and applicability to special populations, offering references for optimizing vaccine selection and vaccination strategies. Additionally, the study addresses the challenges mRNA vaccines face in development, production, distribution, and public acceptance, exploring their future development directions. This provides scientific evidence for future vaccine development and public health decision-making.

mRNA vaccines; Safety; Efficacy; Clinical trials; Vaccine development